Table 2.

Data on prior asthma medication, lung function, patient-recorded outcomes and healthcare utilization recorded before the start of benralizumab therapy (i.e., at the index date or during the 12 months prior to the index date)

Characteristics	Evaluable population N = 205
Corticosteroid use at the index date
ICS/LABA or ICS + LABA
Any ICS dose	205 (100%)
Low ICS dose	3 (1.5%)
Low/Medium ICS dose	16 (7.8%)
Medium ICS dose	6 (2.9%)
High ICS dose	179 (87.3%)
Data unknown	1 (0.5%)
LAMA	104 (50.7%)
Other*	88 (42.9%)
OCS	53 (25.9%)
OCS dosage among users, prednisone-equivalent, mg/die (N = 48)	10 (5–25)
Biologic use during the 12 months prior to the index date
Yes, any biologic	58 (28.3%)
Omalizumab	34 (16.6%)
Mepolizumab	19 (9.3%)
Omalizumab > Mepolizumab	5 (2.4%)
No	147 (71.7%)
Lung function at the index date
Pre-bronchodilator FEV1, L (N = 154)	2.0 ± 0.8
Post-bronchodilator FEV1, L (N = 92)	2.1 ± 0.9
Pre-bronchodilator FEV1, % predicted (N = 159)	70.6 ± 21.6
Post-bronchodilator FEV1, % predicted (N = 90)	75.3 ± 22.9
Pre-bronchodilator FVC, L (N = 148)	3.0 ± 1.0
FeNO, ppb (N = 66)	46.7 ± 34.6
ACT score at the index date (N = 161)	14.7 ± 4.7
AQLQ score at the index date (N = 32)	3.7 ± 1.2
Healthcare resource utilization for asthma per patient during the 12 months prior to the index date (N = 189)
Primary care physician/GP office visits	1.0 ± 2.0
Specialist visits	2.4 ± 3.0
ED admissions	0.2 ± 0.5
Hospitalizations	0.1 ± 0.4

Data are N (%), mean ± SD, or median (IQR). Unless otherwise stated, the evaluable population included 205 patients

ICS inhaled corticosteroid, LABA long-acting β2-agonist, LAMA long-acting muscarinic receptor antagonist, FEV₁ forced expiratory volume in 1 s, FVC forced vital capacity, FeNO fractioned exhaled nitric oxide ACT, asthma control test, AQLQ asthma quality of life questionnaire, GP general practitioner, ED emergency department